Abstracts and additional details can be found at the CNS Summit 2024 website.

The ROS-1 NSCLC current market is mainly dominated by tyrosine kinase inhibitors such as XALKORI at present and is ...

Boston Scientific Corporation will participate in the 2024 UBS Global Healthcare Conference on Tuesday, November 12, 2024.

Torrent Investments, a promoter entity of Torrent Pharmaceuticals, has offloaded a total of 99.44 lakh shares or 2.94 per ...

Total revenues were $175.7 million in the third quarter of 2024, an increase of 14% compared to the same period in 2023. Total revenues excluding Trokendi XR ® and Oxtellar XR ® net product sales (non ...

CNS Pharmaceuticals (NASDAQ: CNSP) , focused on innovative cancer therapies for brain and central nervous system cancers, recently participated in ...

Detailed price information for Cns Pharmaceuticals Inc (CNSP-Q) from The Globe and Mail including charting and trades.

Segment featuring leading Neuro-Oncologist and Glioblastoma Key Opinion Leader, Professor Michael Weller Access the segment ...

Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) announced a remarkable achievement with $186.0 million in net revenue for ...

Schizophrenia significantly shortens life expectancy by an estimated 15 years with excess mortality arising from multiple ...

Supernus Pharmaceuticals (NASDAQ:SUPN – Get Free Report) is scheduled to be announcing its earnings results after the market closes on Monday, November 4th. Analysts expect the company to announce ...

CNS Pharmaceuticals (NASDAQ: CNSP) announced that it received an exception from the nasdaq Hearings Panel, granting the company until March 11, 2025, to meet the minimum bid price requirement under ...